• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of anti-Ang2 therapy for the treatment of diabetic macular edema

Research Project

Project/Area Number 25670732
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Ophthalmology
Research InstitutionNagoya City University (2014)
Kobe University (2013)

Principal Investigator

UEMURA Akiyoshi  名古屋市立大学, 医学(系)研究科(研究院), 教授 (30373278)

Co-Investigator(Renkei-kenkyūsha) FUKUSHIMA Yoko  大阪大学, 大学院医学系研究科, 助教 (70647031)
Project Period (FY) 2013-04-01 – 2015-03-31
Project Status Completed (Fiscal Year 2014)
Budget Amount *help
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords糖尿病黄斑浮腫 / 網膜 / ペリサイト / Ang2 / 炎症 / イメージング / 国際情報交換 / 韓国
Outline of Final Research Achievements

Ant-VEGF therapy has globally become the major modality for the treatment of diabetic macular edema (DME). However, because of its insufficient efficacy, development of new drugs for DME is desired. Here, by utilizing a mouse model of diabetic retinopathy which reproduces retinal edema resulting from loss of pericytes, we observed up-regulation of Angiopoietin-2 (Ang2) in endothelial cells of pericyte-free retinal vessels. Furthermore, intraocular injections of anti-Ang2 blocking antibody suppressed retinal edema even in the absence of pericytes. Given that several pharmaceutical companies have developed a series of anti-Ang2 drugs, anti-Ang2 therapy is expectably feasible for the treatment of DME.

Report

(3 results)
  • 2014 Annual Research Report   Final Research Report ( PDF )
  • 2013 Research-status Report
  • Research Products

    (7 results)

All 2015 2014 2013

All Journal Article (2 results) Presentation (5 results) (of which Invited: 5 results)

  • [Journal Article] Identification of novel drug targets for the treatment of diabetic retinopathy.2013

    • Author(s)
      Uemura A
    • Journal Title

      Diabets Metab J

      Volume: 37 Issue: 4 Pages: 217-224

    • DOI

      10.4093/dmj.2013.37.4.217

    • Related Report
      2013 Research-status Report
  • [Journal Article] 網膜症における血管新生2013

    • Author(s)
      植村 明嘉
    • Journal Title

      糖尿病合併症

      Volume: 27 Pages: 72-75

    • Related Report
      2013 Research-status Report
  • [Presentation] Pathophysiology of pericy-free retinal vessels.2015

    • Author(s)
      Akiyoshi Uemura
    • Organizer
      Asia-ARVO 2015
    • Place of Presentation
      パシフィコ横浜
    • Year and Date
      2015-02-16 – 2015-02-19
    • Related Report
      2014 Annual Research Report
    • Invited
  • [Presentation] Novel molecular targets for the treatment of diabetic retinopathy.2014

    • Author(s)
      Akiyoshi Uemura
    • Organizer
      2014 International Conference on Diabetes and Metabolism
    • Place of Presentation
      韓国イルサンKINTEX
    • Year and Date
      2014-10-16 – 2014-10-18
    • Related Report
      2014 Annual Research Report
    • Invited
  • [Presentation] RhoJ integrates VEGF and Sema3E signals in angiogenic endothelial cells.2013

    • Author(s)
      Uemura A
    • Organizer
      26th Spring Congress of the Korean Diabetes Association & 1st Korea-Japan Diabetes Forum
    • Place of Presentation
      韓国
    • Related Report
      2013 Research-status Report
    • Invited
  • [Presentation] Regulation of ocular angiogenesis and lymphangiogenesis by guidance molecules.2013

    • Author(s)
      Uemura A
    • Organizer
      2nd Cornea Cell Biology Symposium at Wakayama
    • Place of Presentation
      和歌山
    • Related Report
      2013 Research-status Report
    • Invited
  • [Presentation] 糖尿病網膜症に対する創薬標的分子の探索2013

    • Author(s)
      植村 明嘉
    • Organizer
      第67回日本臨床眼科学会
    • Place of Presentation
      横浜
    • Related Report
      2013 Research-status Report
    • Invited

URL: 

Published: 2014-07-25   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi